Oncolys BioPharma, Inc. (JP:4588) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Oncolys BioPharma Inc. reports a decrease in net sales by 50.2% and a significant operating loss for the first half of 2024 compared to the same period in 2023, with no dividends paid or forecasted. The company’s total assets decreased slightly, while the equity ratio increased to 74.7%. Oncolys has not provided a financial forecast for the end of the fiscal year, citing the difficulty of making reasonable estimates.
For further insights into JP:4588 stock, check out TipRanks’ Stock Analysis page.